Abstract
There are theoretical limits to the efficacy of intravesical instillation of anticancer agents as a method to prevent recurrence of superficial bladder cancer. Studies on the direct efficacy of intravesical instillation of bacillus Calmette-Guérin (BCG) to treat existing papillary tumours (Ta, T1) have shown a complete response rate of 66.4% and a partial response rate of 20.8%. These figures represent potent efficacy similar to that of BCG in the treatment of carcinoma in situ (CIS). Moreover, this efficacy was found to persist over a long period of time, and the subsequent recurrence rate was markedly reduced. In cases with multiple tumours, or in subjects where concurrent CIS is strongly suspected, these findings suggest that intravesical instillation of BCG might best be performed prior to transurethral resection of bladder tumours.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
